IRVINE, Calif., June 20, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer, today announced that it has been selected by Pathology, Inc. to be its exclusive provider of chromosomal microarray tests for the Products of Conception (POC) testing market throughout the United States. POC testing, also referred to as miscarriage testing, is a subset of the overall prenatal testing market.
The announcement is an expansion of the previous strategic partnership between the two companies announced in November 2012 that gave Pathology, Inc. the right to market and distribute microarray tests on behalf of CombiMatrix in the states of California and Nevada, as well as the St. Louis and Chicago metropolitan areas.
"The partnership has been very beneficial for both parties to date, and I believe it will benefit our physician partners and their patients to extend the working relationship we have established with CombiMatrix," said Vicki DiFrancesco, President and CEO of Pathology, Inc., a full service, independent Women's Health laboratory based in Torrance, California. "The POC market is an important segment of women's health for Pathology, Inc. and we are pleased to be working with an advanced laboratory like CombiMatrix that specializes in microarray testing. We believe this market is going to continue to expand as our physician customers and their patients realize the importance of microarray testing in helping to identify the causes of miscarriages and how that information may assist in future pregnancies."CombiMatrix President and Chief Executive Officer Mark McDonough said, "The expansion of this partnership underscores the rapidly expanding importance of microarray testing and the value our team brings to Pathology, Inc. in terms of operational and analytical support. Pathology, Inc. is one of the leading women's health labs in the nation and we are very pleased to be recognized by these experts as a valuable partner.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts